nach oben

Erschienen in:

18.09.2017 | Review articles

Quantitative evaluation of PPAR-γ2 Pro12Ala polymorphism with hypertension

verfasst von: W. Yang, J. Wang, W. Ye, Dr. X. Li

Erschienen in: Herz | Ausgabe 8/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

The peroxisome proliferator-activated receptor γ2 (PPARγ2)Pro12Ala polymorphism has been reported to be associated with hypertension. However, relevant studies have shown inconsistent results.

Methods

To quantitatively evaluate the relationship between the PPARγ2Pro12Ala polymorphism and hypertension risk, we conducted a meta-analysis based on all available studies selected from Scopus, Web of Science, PubMed, Chinese National Knowledge Infrastructure, and Wanfang databases.

Results

In all, 13 studies were finally included in this meta-analysis. In the allelic model (Ala vs. Pro), the Ala allele of PPARγ2 Pro12Ala polymorphism was associated with hypertension (Odds Ratio [OR] = 0.723, 95% confidence interval [CI] = 0.607–0.861). Sensitivity analysis and exclusion of studies with poor quality scores or controls complicated by other diseases confirmed the validity of this association. Moreover, the PPARγ2Pro12Ala polymorphism was associated with hypertension in the codominant (OR = 0.710, 95% CI = 0.626–0.806), recessive (OR = 0.561, 95% CI = 0.418–0.754), and dominant (OR = 0.693, 95% CI = 0.577–0.833) models.

Conclusion

The Ala allele appears to have a protective effect against hypertension and a dominant function.

Freeman AJ, Vinh A, Widdop RE (2017) Novel approaches for treating hypertension. F1000Res 6:80CrossRefPubMedPubMedCentral

Brody AM, Kumar VA, Levy PD (2017) Hot topic: global burden of treating hypertension-what is the role of the emergency department? Curr Hypertens Rep 19(1):8CrossRefPubMed

Yang L, Tian RG, Chang PY, Yan MR et al (2015) Association of SNPs in the PPARgamma gene and hypertension in a Mongolian population. Genet Mol Res 14(4):19295–19308CrossRefPubMed

Luft FC (2017) What have we learned from the genetics of hypertension? Med Clin North Am 101(1):195–206CrossRefPubMed

Roszer T, Ricote M (2010) PPARs in the renal regulation of systemic blood pressure. PPAR Res 2010:698730. https://doi.org/10.1155/2010/698730 CrossRefPubMedPubMedCentral

Gao L, Wang L, Yun H, Su L et al (2010) Association of the PPARgamma2 gene Pro12Ala variant with primary hypertension and metabolic lipid disorders in Han Chinese of Inner Mongolia. Genet Mol Res 9(3):1312–1320CrossRefPubMed

Iglarz M, Touyz RM, Amiri F, Lavoie MF et al (2003) Effect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelin-dependent hypertension. Arterioscler Thromb Vasc Biol 23(1):45–51CrossRefPubMed

Diep QN, Amiri F, Benkirane K, Paradis P et al (2004) Long-term effects of the PPAR gamma activator pioglitazone on cardiac inflammation in stroke-prone spontaneously hypertensive rats. Can J Physiol Pharmacol 82(11):976–985CrossRefPubMed

Benkirane K, Viel EC, Amiri F, Schiffrin EL (2006) Peroxisome proliferator-activated receptor gamma regulates angiotensin II-stimulated phosphatidylinositol 3‑kinase and mitogen-activated protein kinase in blood vessels in vivo. Hypertension 47(1):102–108CrossRefPubMed

10.

Tamori Y, Masugi J, Nishino N, Kasuga M (2002) Role of peroxisome proliferator-activated receptor-gamma in maintenance of the characteristics of mature 3T3-L1 adipocytes. Diabetes 51(7):2045–2055CrossRefPubMed

11.

Bener A, Darwish S, Al-Hamaq AO, Mohammad RM et al (2013) Association of PPARgamma2 gene variant Pro12Ala polymorphism with hypertension and obesity in the aboriginal Qatari population known for being consanguineous. Appl Clin Genet 6:103–111CrossRefPubMedPubMedCentral

12.

Gouni-Berthold I, Giannakidou E, Muller-Wieland D, Faust M et al (2005) Peroxisome proliferator-activated receptor-gamma2 Pro12Ala and endothelial nitric oxide synthase-4a/b gene polymorphisms are not associated with hypertension in diabetes mellitus type 2. J Hypertens 23(2):301–308CrossRefPubMed

13.

Gu SJ, Guo ZR, Wu M, Ding Y et al (2013) Association of peroxisome proliferator-activated receptor gamma polymorphisms and haplotypes with essential hypertension. Genet Test Mol Biomarkers 17(5):418–423CrossRefPubMed

14.

Horiki M, Ikegami H, Fujisawa T, Kawabata Y et al (2004) Association of Pro12Ala polymorphism of PPARgamma gene with insulin resistance and related diseases. Diabetes Res Clin Pract 66(Suppl 1):S63–S67CrossRefPubMed

15.

Hui P, Nakayama T, Morita A, Sato N et al (2007) Common single nucleotide polymorphisms in Japanese patients with essential hypertension: aldehyde dehydrogenase 2 gene as a risk factor independent of alcohol consumption. Hypertension 30(7):585–592

16.

Kim K, Lee S, Valentine RJ (2007) Association of pro12Ala polymorphism in the peroxisome proliferative-activated receptor gamma2 gene with obesity and hypertension in Korean women. J Nutr Sci Vitaminol 53(3):239–246CrossRefPubMed

17.

Lu Z, Dong B, Mo X, Chen T et al (2008) Pro12Ala polymorphism in PPAR gamma 2 associated with essential hypertension in Chinese nonagenarians/centenarians. Exp Gerontol 43(12):1108–1113CrossRefPubMed

18.

Ostgren CJ, Lindblad U, Melander O, Melander A et al (2003) Peroxisome proliferator-activated receptor-gammaPro12Ala polymorphism and the association with blood pressure in type 2 diabetes: skaraborg hypertension and diabetes project. J Hypertens 21(9):1657–1662CrossRefPubMed

19.

Rodriguez-Esparragon FJ, Rodriguez-Perez JC, Macias-Reyes A, Alamo-Santana F (2003) Peroxisome proliferator-activated receptor-gamma2-Pro12Ala and endothelial nitric oxide synthase-4a/bgene polymorphisms are associated with essential hypertension. J Hypertens 21(9):1649–1655CrossRef

20.

Sookoian S, Garcia SI, Porto PI, Dieuzeide G et al (2005) Peroxisome proliferator-activated receptor gamma and its coactivator-1 alpha may be associated with features of the metabolic syndrome in adolescents. J Mol Endocrinol 35(2):373–380CrossRefPubMed

21.

Wang G, Xu P, Feng W, Jiang X et al (2015) Case-control study on peroxisome proliferator-activated receptor gamma polymorphism and interaction with HDL on essential hypertension in Chinese Han. Iran J Basic Med Sci 18(12):1228–1232PubMedPubMedCentral

22.

Zhang A, Zhang M, Zhang J, Yu Y et al (2005) The influence of the Pro12Ala mutation of PPARgamma2 receptor gene on beta-cells restoration and insulin resistance in type 2 diabetes with hypertension. J Huazhong Univ Sci Technol Med Sci 25(6):648–650CrossRefPubMed

23.

Shen D, Ha DW (2004) Relationship between PPAR γ2 gene pro12Ala polymorphism hypertension and blood lipids. Chin J Hypertens 12(4):319–322

24.

Dong HR, Han FQ, Su XL (2012) The relationship between peroxis ome proliferator-activated receptor γ and its coactivated 1α and mongolian hypertension. Int J Lab Med 33(22):2698–2700

25.

Chen J, Zhang M, Liu JM, Ma RL et al (2014) Association of PPARγ gene polymorphism with hypertension in Xinjiang Uygur. J Pract Med 30(18):2922–2925

26.

Pan HJ, Guo YY, Wang G, Zhao L et al (2007) Additive effects of the variants in the β3-AR and PPAR-γ2 genes on essential hypertension in Xinjiang kazakh population. Chin J Birth Health Hered 15(3):19–21

27.

Wang Y, Liu C (2012) Quantitative evaluation of common polymorphism (rs1801282) in the PPARgamma2 gene and hypertension susceptibility. Gene 502(2):159–162CrossRefPubMed

28.

Hou X, Chen X, Shi J (2015) Genetic polymorphism of MTHFR C677T and premature coronary artery disease susceptibility: a meta-analysis. Gene 565(1):39–44CrossRefPubMed

29.

Yang W, Zhu Z, Wang J, Ye W et al (2015) Evaluation of the relationship between T663A polymorphism in the alpha-epithelial sodium channel gene and essential hypertension. Saudi Med J 36(9):1039–1045CrossRefPubMedPubMedCentral

30.

Yliharsila H, Eriksson JG, Forsen T, Laakso M et al (2004) Interactions between peroxisome proliferator-activated receptor-gamma 2 gene polymorphisms and size at birth on blood pressure and the use of antihypertensive medication. J Hypertens 22(7):1283–1287CrossRefPubMed

31.

Takeda K, Ichiki T, Tokunou T, Funakoshi Y et al (2000) Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. Circulation 102(15):1834–1839CrossRefPubMed

32.

Ji Y, Liu J, Wang Z, Liu N et al (2009) PPARgamma agonist, rosiglitazone, regulates angiotensin II-induced vascular inflammation through the TLR4-dependent signaling pathway. Lab Invest 89(8):887–902CrossRefPubMed

33.

Sugawara A, Takeuchi K, Uruno A, Ikeda Y et al (2001) Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-gamma in vascular smooth muscle cells. Endocrinology 142(7):3125–3134CrossRefPubMed

34.

Lehrke M, Lazar MA (2005) The many faces of PPARgamma. Cell 123(6):993–999CrossRefPubMed

Titel: Quantitative evaluation of PPAR-γ2 Pro12Ala polymorphism with hypertension
verfasst von: W. Yang
J. Wang
W. Ye
Dr. X. Li
Publikationsdatum: 18.09.2017
Verlag: Springer Medizin
Erschienen in: Herz / Ausgabe 8/2018
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI: https://doi.org/10.1007/s00059-017-4618-6

Neu im Fachgebiet Kardiologie

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

VHF-Ablation nützt wohl nur bei reduzierter Auswurfleistung

02.05.2024 Ablationstherapie Nachrichten

Ob die Katheterablation von Vorhofflimmern bei Patienten mit Herzinsuffizienz die Komplikationsraten senkt, scheint davon abzuhängen, ob die Auswurfleistung erhalten ist oder nicht. Das legen die Ergebnisse einer Metaanalyse nahe.

Weniger Extremitätenischämien mit dualer Plättchenhemmung

02.05.2024 Thrombozytenaggregationshemmer Nachrichten

Eine Behandlung mit Ticagrelor zusätzlich zu ASS kann das Risiko für Revaskularisierungen und Amputationen von Extremitäten bei Diabetikern mit stabiler KHK deutlich reduzieren, vor allem für solche mit PAVK. Dafür spricht eine Auswertung der Interventionsstudie THEMIS.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2018

Effect of pioglitazone on inflammation and calcification in atherosclerotic rabbits

ESC/EACTS-Leitlinien zur Myokardrevaskularisation 2018

Transcatheter aortic valve replacement with balloon-expandable valve

Neue ESC-Leitlinie Synkope – was hat sich geändert?